Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactobacillus CD2 for Oral Mucositis in HSCT
NCT01480011Phase 2Completed
- Sponsor
- AIIMS New Delhi
- Start
- Nov 2011
- Primary completion
- Sep 2012
- Modality
- Yeast Strains, Defined Consortia, Bacterial Strains
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lactobacillus brevis cd2 in oral mucositis (OM), sponsored by AIIMS New Delhi. Primary endpoint: Incidence of WHO Grade III and Grade IV Oral Mucositis. Started Nov 2011; status: completed.
02
Drugs
lactobacillus brevis cd2
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT01480011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01480011.